Cargando…

Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma

BACKGROUND: Ripretinib, a broad-spectrum KIT and platelet-derived growth factor receptor A switch-control tyrosine kinase inhibitor, is approved for the treatment of adult patients with advanced gastrointestinal stromal tumor as ≥ fourth-line therapy. We present the efficacy and safety of ripretinib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Janku, F., Bauer, S., Shoumariyeh, K., Jones, R.L., Spreafico, A., Jennings, J., Psoinos, C., Meade, J., Ruiz-Soto, R., Chi, P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434165/ https://www.ncbi.nlm.nih.gov/pubmed/35753087 http://dx.doi.org/10.1016/j.esmoop.2022.100520

Ejemplares similares

Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib
por: Janku, Filip, et al.
Publicado: (2020)

Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study
por: Bauer, Sebastian, et al.
Publicado: (2021)

Effects of CYP3A Inhibition, CYP3A Induction, and Gastric Acid Reduction on the Pharmacokinetics of Ripretinib, a Switch Control KIT Tyrosine Kinase Inhibitor
por: Li, Xiaoyan, et al.
Publicado: (2022)

Multi-disciplinary management of recurrent gastrointestinal stromal tumor harboring KIT exon 11 mutation with the switch-control kinase inhibitor ripretinib and surgery
por: Gouda, Mohamed A., et al.
Publicado: (2023)

Ripretinib: First Approval
por: Dhillon, Sohita
Publicado: (2020)

Correction to: Ripretinib: First Approval
por: Dhillon, Sohita
Publicado: (2020)

Ripretinib for gastrointestinal stromal tumours
Publicado: (2021)

Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study
por: Zalcberg, John R., et al.
Publicado: (2021)

Ripretinib for the treatment of advanced gastrointestinal stromal tumor
por: Zalcberg, John R.
Publicado: (2021)

Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial
por: Schöffski, Patrick, et al.
Publicado: (2022)

Compassionate Use of Ripretinib for Patients With Metastatic Gastrointestinal Stromal Tumors: Taiwan and Hong Kong Experience
por: Lin, Li-Ching, et al.
Publicado: (2022)

Emerging Data on the Safety and Efficacy of Ripretinib for the Treatment of Gastrointestinal Stromal Tumors
por: Thirasastr, Prapassorn, et al.
Publicado: (2023)

Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial
por: Bauer, Sebastian, et al.
Publicado: (2022)

Corrigendum: Compassionate use of ripretinib for patients with metastatic gastrointestinal stromal tumors: Taiwan and Hong Kong experience
por: Lin, Li-Ching, et al.
Publicado: (2022)

Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward
por: Lostes-Bardaji, M. Julia, et al.
Publicado: (2021)

Systemic mastocytosis, in the context of a deleterious germline SDHC variant, treated with ripretinib
por: Saheb Kashaf, Sara, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Fourth- or Further-Line Ripretinib in Advanced Gastrointestinal Stromal Tumors
por: Liao, Weiting, et al.
Publicado: (2021)

The Pharmacokinetic Effect of Itraconazole and Voriconazole on Ripretinib in Beagle Dogs by UPLC-MS/MS Technique
por: Wang, Hui-jun, et al.
Publicado: (2021)

Management of Patients With Advanced Gastrointestinal Stromal Tumor: Emphasis on Fourth-Line Treatment With Ripretinib
por: Brackert, Sandra, et al.
Publicado: (2023)

The Pharmacokinetic Effect of Itraconazole and Voriconazole on Ripretinib in Beagle Dogs by UPLC-MS/MS Technique [Corrigendum]
Publicado: (2023)

Efficacy and safety of ripretinib in Chinese patients with advanced gastrointestinal stromal tumors: a real-world, multicenter, observational study
por: Yang, Weili, et al.
Publicado: (2023)

Comparison of c-Kit expression between primary and metastatic melanoma of skin and mucosa
por: Sari Aslani, Fatemeh, et al.
Publicado: (2015)

The clinical significance of c-Kit mutations in metastatic oral mucosal melanoma in China
por: Ma, Xuhui, et al.
Publicado: (2017)

Response to Imatinib in a Patient with Double-mutant KIT Metastatic Penile Melanoma
por: BEAUDOUX, Olivia, et al.
Publicado: (2021)

Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas
por: Satzger, I, et al.
Publicado: (2008)

LMTK3 is essential for oncogenic KIT expression in KIT-mutant GIST and melanoma
por: Klug, Lillian R., et al.
Publicado: (2018)

Large-Scale, Multicenter, Prospective Registry Study of Ripretinib in Advanced GIST: A Real-World Study from China
por: Zhang, Xinhua, et al.
Publicado: (2023)

Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial
por: Guo, J., et al.
Publicado: (2017)

KIT and Melanoma: Biological Insights and Clinical Implications
por: Pham, Duc (Daniel) M., et al.
Publicado: (2020)

Resistance to c-Kit inhibitors in melanoma: insights for future therapies
por: Carlino, Matteo S., et al.
Publicado: (2014)

Ultrasensitive detection of BRAF mutations in circulating tumor DNA of non-metastatic melanoma
por: Gouda, M.A., et al.
Publicado: (2021)

Genotyping guided ripretinib directly after the progression of first-line imatinib therapy in advanced gastrointestinal stromal tumor: a case report
por: Huang, Shaoqing, et al.
Publicado: (2022)

The role of c-kit and imatinib mesylate in uveal melanoma
por: Pereira, Patricia Rusa, et al.
Publicado: (2005)

Amelanotic Acral Melanoma Associated with KIT Mutation and Vitiligo
por: Kim, Young Jee, et al.
Publicado: (2015)

KIT Mutation Incidence and Pattern of Melanoma in Central Europe
por: Doma, V., et al.
Publicado: (2019)

A rapid and sensitive UPLC-MS/MS method for simultaneous determination of four potential mutagenic impurities at trace levels in ripretinib drug substance
por: Huang, Yiwen, et al.
Publicado: (2022)

Molecular Alterations of KIT Oncogene in Gliomas
por: Gomes, Ana L., et al.
Publicado: (2007)

Differences in and verification of genetic alterations in chemotherapy and immunotherapy for metastatic melanoma
por: Li, Yang, et al.
Publicado: (2021)

Ripretinib in combination with tyrosine kinase inhibitor as a late-line treatment option for refractory gastrointestinal stromal tumors: two case reports and literature review
por: Zhang, Yefan, et al.
Publicado: (2023)

Efficacy and Safety of Ripretinib in Chinese Patients with Advanced Gastrointestinal Stromal Tumors as a Fourth- or Later-Line Therapy: A Multicenter, Single-Arm, Open-Label Phase II Study
por: Li, Jian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1586f4kcaloadvcvrknmb7g2tl